Skip to main content
Top
Published in: BMC Geriatrics 1/2021

Open Access 01-12-2021 | Care | Research

Effects of physician visit frequency for Parkinson’s disease treatment on mortality, hospitalization, and costs: a retrospective cohort study

Authors: Takako Fujita, Akira Babazono, Sung-a Kim, Aziz Jamal, Yunfei Li

Published in: BMC Geriatrics | Issue 1/2021

Login to get access

Abstract

Background

The number of patients with Parkinson’s disease among older adults is rapidly increasing. Such patients mostly take medication and require regular physician visits. However, the effect of physician visit frequency for the treatment for Parkinson’s disease has not been evaluated. This study aimed to evaluate the impact of physician visit frequency for Parkinson’s disease treatment on mortality, healthcare days, and healthcare and long-term care costs among older adults.

Methods

This study employed a retrospective cohort design utilizing claims data from the Fukuoka Prefecture Wide-Area Association of Latter-Stage Elderly Healthcare Insurance and Long-Term Care Insurance. Patients aged ≥75 years who were newly diagnosed with Parkinson’s disease in 2014 were included in this study, following the onset of Parkinson’s disease to March 31, 2019. We calculated the restricted mean survival time to evaluate mortality, focusing on the frequency of physician visits for Parkinson’s disease treatment. Inpatient days, outpatient days, and healthcare and long-term care costs per month were calculated using a generalized linear model.

Results

There were 2224 participants, with 46.5% mortality among those with a higher frequency of physician visits and 56.4% among those with a lower frequency of physician visits. A higher frequency of physician visits was associated with a significant increase in survival time (1.57 months at 24 months and 5.00 months at 60 months) after the onset of Parkinson’s disease and a decrease in inpatient days and healthcare costs compared to a lower frequency of physician visits.

Conclusions

A higher frequency of physician visits was significantly associated with longer survival time, fewer inpatient days, and lower healthcare costs. Caregivers should support patients with Parkinson’s disease to visit physicians regularly for their treatment.
Literature
1.
go back to reference Ray Dorsey E, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):939–53.CrossRef Ray Dorsey E, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):939–53.CrossRef
4.
go back to reference Poortvliet PC, Gluch A, Silburn PA, Mellick GD. The Queensland Parkinson’s project: an overview of 20 years of mortality from Parkinson’s disease. J Mov Disord. 2021;14(1):34–41.CrossRef Poortvliet PC, Gluch A, Silburn PA, Mellick GD. The Queensland Parkinson’s project: an overview of 20 years of mortality from Parkinson’s disease. J Mov Disord. 2021;14(1):34–41.CrossRef
5.
go back to reference Macleod AD, Taylor KSM, Counsell CE. Mortality in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615–22.CrossRef Macleod AD, Taylor KSM, Counsell CE. Mortality in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615–22.CrossRef
7.
go back to reference Bäckström D, Granåsen G, Domellöf ME, Linder J, Mo SJ, Riklund K, et al. Early predictors of mortality in parkinsonism and Parkinson disease a population-based study. Neurology. 2018;91(22):E2045–56.CrossRef Bäckström D, Granåsen G, Domellöf ME, Linder J, Mo SJ, Riklund K, et al. Early predictors of mortality in parkinsonism and Parkinson disease a population-based study. Neurology. 2018;91(22):E2045–56.CrossRef
8.
go back to reference Wanneveich M, Moisan F, Jacqmin-Gadda H, Elbaz A, Joly P. Projections of prevalence, lifetime risk, and life expectancy of Parkinson’s disease (2010-2030) in France. Mov Disord. 2018;33(9):1449–55.CrossRef Wanneveich M, Moisan F, Jacqmin-Gadda H, Elbaz A, Joly P. Projections of prevalence, lifetime risk, and life expectancy of Parkinson’s disease (2010-2030) in France. Mov Disord. 2018;33(9):1449–55.CrossRef
10.
go back to reference Matsuda S, Muramatsu K, Hayashida K. Eligibility classification logic of the Japanese long term care insurance. Asian Pacific J Dis Manag. 2011;5(3):65–74.CrossRef Matsuda S, Muramatsu K, Hayashida K. Eligibility classification logic of the Japanese long term care insurance. Asian Pacific J Dis Manag. 2011;5(3):65–74.CrossRef
11.
go back to reference Matsuda T, Iwagami M, Suzuki T, Jin X, Watanabe T, Tamiya N. Correlation between the Barthel index and care need levels in the Japanese long-term care insurance system. Geriatr Gerontol Int. 2019;19(11):1186–7.CrossRef Matsuda T, Iwagami M, Suzuki T, Jin X, Watanabe T, Tamiya N. Correlation between the Barthel index and care need levels in the Japanese long-term care insurance system. Geriatr Gerontol Int. 2019;19(11):1186–7.CrossRef
12.
13.
15.
go back to reference Cronin A, Tian L, Uno H. strmst2 and strmst2pw: new commands to compare survival curves using the restricted mean survival time. Stata J. 2016;16(3):702–16.CrossRef Cronin A, Tian L, Uno H. strmst2 and strmst2pw: new commands to compare survival curves using the restricted mean survival time. Stata J. 2016;16(3):702–16.CrossRef
17.
go back to reference Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson’s disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry. 2015;86(3):324–9.CrossRef Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson’s disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry. 2015;86(3):324–9.CrossRef
19.
go back to reference Kim S-A, Babazono A, Jamal A, Li Y, Liu N. Comparison of care utilisation and medical institutional death among older adults by home care facility type: a retrospective cohort study in Fukuoka, Japan. BMJ Open. 2021;11(4):e041964.CrossRef Kim S-A, Babazono A, Jamal A, Li Y, Liu N. Comparison of care utilisation and medical institutional death among older adults by home care facility type: a retrospective cohort study in Fukuoka, Japan. BMJ Open. 2021;11(4):e041964.CrossRef
20.
go back to reference Pinter B, Diem-Zangerl A, Wenning GK, Scherfler C, Oberaigner W, Seppi K, et al. Mortality in Parkinson’s disease: a 38-year follow-up study. Mov Disord. 2015;30(2):266–9.CrossRef Pinter B, Diem-Zangerl A, Wenning GK, Scherfler C, Oberaigner W, Seppi K, et al. Mortality in Parkinson’s disease: a 38-year follow-up study. Mov Disord. 2015;30(2):266–9.CrossRef
21.
go back to reference Keener AM, Paul KC, Folle A, Bronstein JM, Ritz B. Cognitive impairment and mortality in a population-based Parkinson’s disease cohort. J Parkinsons Dis. 2018;8(2):353–62.CrossRef Keener AM, Paul KC, Folle A, Bronstein JM, Ritz B. Cognitive impairment and mortality in a population-based Parkinson’s disease cohort. J Parkinsons Dis. 2018;8(2):353–62.CrossRef
22.
go back to reference Abraham DS, Pham Nguyen TP, Willis AW. Claims-based frailty and outcomes: applying an aging measure to older adults with Parkinson’s disease. Mov Disord. 2021;36(8):1871–8.CrossRef Abraham DS, Pham Nguyen TP, Willis AW. Claims-based frailty and outcomes: applying an aging measure to older adults with Parkinson’s disease. Mov Disord. 2021;36(8):1871–8.CrossRef
23.
go back to reference Vossius C, Nilsen OB, Larsen JP. Health state values during the first year of drug treatment in early-stage Parkinsons disease: a prospective, population-based, cohort study. Drugs Aging. 2009;26(11):973–80.CrossRef Vossius C, Nilsen OB, Larsen JP. Health state values during the first year of drug treatment in early-stage Parkinsons disease: a prospective, population-based, cohort study. Drugs Aging. 2009;26(11):973–80.CrossRef
24.
go back to reference Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol. 2012;69(3):380–4.CrossRef Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol. 2012;69(3):380–4.CrossRef
25.
go back to reference Der LK, Yang CY, Lee MY, Ho SC, Liu CK, Shin SJ. Statin therapy prevents the onset of Parkinson disease in patients with diabetes. Ann Neurol. 2016;80(4):532–40.CrossRef Der LK, Yang CY, Lee MY, Ho SC, Liu CK, Shin SJ. Statin therapy prevents the onset of Parkinson disease in patients with diabetes. Ann Neurol. 2016;80(4):532–40.CrossRef
28.
go back to reference Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord. 2013;28(3):311–8.CrossRef Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord. 2013;28(3):311–8.CrossRef
32.
go back to reference El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication adherence in older patients with dementia: a systematic literature review. J Pharm Pract. 2018;31(3):322–34.CrossRef El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication adherence in older patients with dementia: a systematic literature review. J Pharm Pract. 2018;31(3):322–34.CrossRef
33.
go back to reference Lennaerts H, Groot M, Rood B, Gilissen K, Tulp H, Van Wensen E, et al. A guideline for Parkinson’s disease nurse specialists, with recommendations for clinical practice. J Parkinsons Dis. 2017;7(4):749–54.CrossRef Lennaerts H, Groot M, Rood B, Gilissen K, Tulp H, Van Wensen E, et al. A guideline for Parkinson’s disease nurse specialists, with recommendations for clinical practice. J Parkinsons Dis. 2017;7(4):749–54.CrossRef
34.
go back to reference Radder DLM, Lennaerts HH, Vermeulen H, Van Asseldonk T, Delnooz CCS, Hagen RH, et al. The cost-effectiveness of specialized nursing interventions for people with Parkinson’s disease: the NICE-PD study protocol for a randomized controlled clinical trial. Trials. 2020;21(1):1–11.CrossRef Radder DLM, Lennaerts HH, Vermeulen H, Van Asseldonk T, Delnooz CCS, Hagen RH, et al. The cost-effectiveness of specialized nursing interventions for people with Parkinson’s disease: the NICE-PD study protocol for a randomized controlled clinical trial. Trials. 2020;21(1):1–11.CrossRef
Metadata
Title
Effects of physician visit frequency for Parkinson’s disease treatment on mortality, hospitalization, and costs: a retrospective cohort study
Authors
Takako Fujita
Akira Babazono
Sung-a Kim
Aziz Jamal
Yunfei Li
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2021
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-021-02685-x

Other articles of this Issue 1/2021

BMC Geriatrics 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.